| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Meta-Analysis as Topic | 18 | 2020 | 78 | 3.730 |
Why?
|
| Research Design | 10 | 2024 | 585 | 2.700 |
Why?
|
| Models, Statistical | 17 | 2024 | 309 | 2.570 |
Why?
|
| Odds Ratio | 12 | 2024 | 755 | 1.690 |
Why?
|
| Clinical Trials as Topic | 9 | 2020 | 460 | 1.590 |
Why?
|
| Data Interpretation, Statistical | 11 | 2024 | 195 | 1.580 |
Why?
|
| Computer Simulation | 15 | 2024 | 484 | 1.220 |
Why?
|
| Chronic Pain | 2 | 2019 | 149 | 0.960 |
Why?
|
| Probability | 7 | 2023 | 168 | 0.950 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2024 | 800 | 0.840 |
Why?
|
| Algorithms | 5 | 2023 | 1040 | 0.830 |
Why?
|
| Benzenesulfonates | 2 | 2013 | 13 | 0.760 |
Why?
|
| Sirolimus | 2 | 2013 | 93 | 0.730 |
Why?
|
| Pyridines | 2 | 2013 | 116 | 0.710 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2013 | 113 | 0.690 |
Why?
|
| Multiple Sclerosis | 5 | 2023 | 226 | 0.680 |
Why?
|
| Likelihood Functions | 4 | 2019 | 68 | 0.670 |
Why?
|
| Kidney Neoplasms | 2 | 2013 | 173 | 0.660 |
Why?
|
| Sample Size | 6 | 2023 | 66 | 0.650 |
Why?
|
| Endpoint Determination | 2 | 2019 | 27 | 0.640 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 76 | 0.620 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 142 | 0.580 |
Why?
|
| Health | 1 | 2018 | 30 | 0.560 |
Why?
|
| Bias | 5 | 2023 | 116 | 0.560 |
Why?
|
| Treatment Outcome | 9 | 2024 | 5775 | 0.550 |
Why?
|
| Anesthesia | 5 | 2017 | 52 | 0.540 |
Why?
|
| Humans | 69 | 2024 | 64901 | 0.530 |
Why?
|
| Propofol | 1 | 2017 | 21 | 0.510 |
Why?
|
| Software | 2 | 2018 | 394 | 0.510 |
Why?
|
| Review Literature as Topic | 2 | 2015 | 40 | 0.480 |
Why?
|
| Confidence Intervals | 2 | 2016 | 236 | 0.470 |
Why?
|
| Health Status Indicators | 2 | 2015 | 94 | 0.460 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 10 | 0.460 |
Why?
|
| Endometrial Ablation Techniques | 1 | 2013 | 6 | 0.400 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2013 | 7 | 0.400 |
Why?
|
| Menorrhagia | 1 | 2013 | 19 | 0.390 |
Why?
|
| Menstruation | 1 | 2013 | 34 | 0.390 |
Why?
|
| Biomedical Research | 1 | 2015 | 270 | 0.370 |
Why?
|
| Economics, Pharmaceutical | 1 | 2011 | 1 | 0.350 |
Why?
|
| Research Report | 1 | 2011 | 26 | 0.340 |
Why?
|
| Advisory Committees | 1 | 2011 | 111 | 0.330 |
Why?
|
| Pathology | 1 | 2010 | 12 | 0.320 |
Why?
|
| Regression Analysis | 7 | 2019 | 498 | 0.310 |
Why?
|
| Schools, Medical | 1 | 2010 | 150 | 0.300 |
Why?
|
| Statistics as Topic | 4 | 2016 | 146 | 0.280 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 326 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 735 | 0.250 |
Why?
|
| Time Factors | 10 | 2020 | 3755 | 0.230 |
Why?
|
| Female | 29 | 2023 | 33861 | 0.200 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 862 | 0.190 |
Why?
|
| Male | 30 | 2023 | 30898 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 494 | 0.180 |
Why?
|
| Pre-Eclampsia | 2 | 2020 | 70 | 0.180 |
Why?
|
| Diagnosis | 2 | 2014 | 5 | 0.180 |
Why?
|
| Burns | 4 | 1989 | 45 | 0.170 |
Why?
|
| Risk | 2 | 2019 | 374 | 0.170 |
Why?
|
| Mesalamine | 1 | 2020 | 4 | 0.170 |
Why?
|
| Suicide | 1 | 2023 | 144 | 0.170 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2020 | 3 | 0.160 |
Why?
|
| Pain Measurement | 2 | 2019 | 340 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2019 | 2092 | 0.160 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2020 | 34 | 0.150 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2019 | 19 | 0.150 |
Why?
|
| Disease Progression | 3 | 2020 | 1214 | 0.150 |
Why?
|
| Linear Models | 6 | 2021 | 406 | 0.150 |
Why?
|
| International Classification of Diseases | 3 | 2008 | 136 | 0.140 |
Why?
|
| Physical Examination | 2 | 2018 | 110 | 0.140 |
Why?
|
| Endoscopy | 2 | 2017 | 94 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2019 | 575 | 0.140 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 928 | 0.140 |
Why?
|
| Biomarkers | 1 | 2023 | 1473 | 0.140 |
Why?
|
| Health Care Surveys | 3 | 2005 | 288 | 0.140 |
Why?
|
| Adolescent | 15 | 2008 | 6283 | 0.130 |
Why?
|
| Demography | 3 | 2007 | 178 | 0.130 |
Why?
|
| Risk Adjustment | 2 | 2008 | 94 | 0.130 |
Why?
|
| Interviews as Topic | 4 | 2008 | 528 | 0.130 |
Why?
|
| Sclerotherapy | 1 | 2017 | 9 | 0.130 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2017 | 15 | 0.130 |
Why?
|
| Oximetry | 4 | 1993 | 49 | 0.130 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 73 | 0.120 |
Why?
|
| Adult | 19 | 2014 | 17278 | 0.120 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2015 | 8 | 0.120 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2015 | 6 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 182 | 0.110 |
Why?
|
| Veterans | 1 | 2023 | 758 | 0.110 |
Why?
|
| Middle Aged | 16 | 2023 | 18169 | 0.110 |
Why?
|
| Hospital Mortality | 3 | 2008 | 873 | 0.110 |
Why?
|
| Bayes Theorem | 2 | 2013 | 125 | 0.110 |
Why?
|
| Hemagglutinins, Viral | 1 | 2014 | 11 | 0.110 |
Why?
|
| Obesity | 2 | 2012 | 1264 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2015 | 178 | 0.110 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 33 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 71 | 0.110 |
Why?
|
| Mitochondria, Liver | 1 | 2014 | 13 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2015 | 231 | 0.100 |
Why?
|
| Sirtuin 3 | 1 | 2014 | 11 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 525 | 0.100 |
Why?
|
| Diarrhea | 1 | 2014 | 74 | 0.100 |
Why?
|
| Empirical Research | 1 | 2013 | 15 | 0.100 |
Why?
|
| Longevity | 1 | 2015 | 117 | 0.100 |
Why?
|
| Drug Labeling | 1 | 2014 | 23 | 0.100 |
Why?
|
| Computer Graphics | 1 | 1993 | 19 | 0.100 |
Why?
|
| Oxidative Phosphorylation | 1 | 2014 | 42 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2018 | 522 | 0.100 |
Why?
|
| Danazol | 1 | 2013 | 1 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1993 | 45 | 0.100 |
Why?
|
| Levonorgestrel | 1 | 2013 | 10 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2014 | 86 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1993 | 42 | 0.100 |
Why?
|
| Progestins | 1 | 2013 | 29 | 0.100 |
Why?
|
| Migraine Disorders | 1 | 2014 | 45 | 0.100 |
Why?
|
| Health Surveys | 2 | 2006 | 317 | 0.100 |
Why?
|
| Drainage, Postural | 1 | 1993 | 2 | 0.100 |
Why?
|
| United States | 10 | 2010 | 8062 | 0.100 |
Why?
|
| Hospitalization | 1 | 2020 | 1379 | 0.100 |
Why?
|
| Abdomen | 1 | 1993 | 94 | 0.090 |
Why?
|
| Immunization Programs | 2 | 2003 | 14 | 0.090 |
Why?
|
| Waist Circumference | 1 | 2012 | 47 | 0.090 |
Why?
|
| Depression | 1 | 2019 | 897 | 0.090 |
Why?
|
| Aged | 12 | 2015 | 14882 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2014 | 203 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 3 | 2006 | 252 | 0.090 |
Why?
|
| Oxygen | 1 | 1993 | 317 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2012 | 889 | 0.080 |
Why?
|
| Calcium Chloride | 2 | 1988 | 19 | 0.080 |
Why?
|
| Women's Rights | 1 | 2010 | 7 | 0.080 |
Why?
|
| Longitudinal Studies | 4 | 2008 | 1276 | 0.080 |
Why?
|
| Physicians, Women | 1 | 2010 | 41 | 0.080 |
Why?
|
| Diuretics | 2 | 2020 | 58 | 0.080 |
Why?
|
| Analysis of Variance | 4 | 2020 | 603 | 0.070 |
Why?
|
| Cimetidine | 1 | 1989 | 3 | 0.070 |
Why?
|
| Cosmetics | 1 | 1988 | 16 | 0.070 |
Why?
|
| Color | 1 | 1988 | 25 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2008 | 1103 | 0.070 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2008 | 16 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 803 | 0.070 |
Why?
|
| Neuromuscular Junction | 1 | 1988 | 83 | 0.070 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2008 | 34 | 0.070 |
Why?
|
| Nails | 1 | 1988 | 39 | 0.070 |
Why?
|
| Adiposity | 1 | 2008 | 83 | 0.070 |
Why?
|
| Neurology | 1 | 2008 | 44 | 0.070 |
Why?
|
| Insurance Claim Review | 1 | 2007 | 75 | 0.070 |
Why?
|
| Immunization | 2 | 2005 | 136 | 0.070 |
Why?
|
| Gluconates | 1 | 1987 | 4 | 0.070 |
Why?
|
| Succinylcholine | 1 | 1987 | 10 | 0.070 |
Why?
|
| Calcium Gluconate | 1 | 1987 | 6 | 0.060 |
Why?
|
| Infant | 8 | 2005 | 1677 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2008 | 246 | 0.060 |
Why?
|
| Child, Preschool | 9 | 2005 | 2049 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 433 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 2 | 2008 | 346 | 0.060 |
Why?
|
| Logistic Models | 5 | 2014 | 1268 | 0.060 |
Why?
|
| Hospitals | 2 | 2007 | 385 | 0.060 |
Why?
|
| Potassium | 1 | 1987 | 97 | 0.060 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 46 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 1987 | 40 | 0.060 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 1986 | 15 | 0.060 |
Why?
|
| Isoquinolines | 1 | 1986 | 30 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1987 | 152 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 380 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 1133 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 5582 | 0.060 |
Why?
|
| Income | 1 | 2007 | 169 | 0.060 |
Why?
|
| Educational Status | 1 | 2007 | 277 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2014 | 2609 | 0.060 |
Why?
|
| Employment | 1 | 2007 | 132 | 0.060 |
Why?
|
| Random Allocation | 5 | 2005 | 200 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 105 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2008 | 586 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2018 | 371 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 141 | 0.060 |
Why?
|
| Stroke | 2 | 2018 | 1207 | 0.050 |
Why?
|
| Health Status | 2 | 2006 | 448 | 0.050 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2023 | 19 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2006 | 296 | 0.050 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2003 | 9 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2007 | 881 | 0.050 |
Why?
|
| Pennsylvania | 3 | 2008 | 66 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2023 | 131 | 0.050 |
Why?
|
| Capsid Proteins | 1 | 2023 | 105 | 0.050 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 104 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2023 | 52 | 0.050 |
Why?
|
| Pregnancy | 2 | 2020 | 2366 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 198 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 1690 | 0.040 |
Why?
|
| Air Pollution | 1 | 2001 | 40 | 0.040 |
Why?
|
| Massachusetts | 2 | 2006 | 2138 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2014 | 3303 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 150 | 0.040 |
Why?
|
| Air Pollutants | 1 | 2001 | 98 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2007 | 1314 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2023 | 1134 | 0.040 |
Why?
|
| Quality of Life | 1 | 2007 | 1257 | 0.040 |
Why?
|
| Least-Squares Analysis | 2 | 1996 | 24 | 0.040 |
Why?
|
| Risk Factors | 4 | 2014 | 5404 | 0.040 |
Why?
|
| Information Systems | 1 | 2018 | 28 | 0.040 |
Why?
|
| Hypocalcemia | 2 | 1989 | 19 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2018 | 31 | 0.040 |
Why?
|
| Telephone | 3 | 2005 | 122 | 0.040 |
Why?
|
| Publication Bias | 1 | 2018 | 21 | 0.040 |
Why?
|
| Activities of Daily Living | 3 | 2008 | 293 | 0.030 |
Why?
|
| Clinical Laboratory Information Systems | 2 | 2008 | 3 | 0.030 |
Why?
|
| Insurance Claim Reporting | 2 | 2008 | 17 | 0.030 |
Why?
|
| Dogs | 3 | 1989 | 316 | 0.030 |
Why?
|
| Recurrence | 2 | 2008 | 655 | 0.030 |
Why?
|
| Health Priorities | 1 | 1997 | 29 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 147 | 0.030 |
Why?
|
| Auranofin | 1 | 1996 | 3 | 0.030 |
Why?
|
| Surveys and Questionnaires | 5 | 2007 | 2757 | 0.030 |
Why?
|
| Patient Admission | 2 | 2007 | 197 | 0.030 |
Why?
|
| Insurance, Health | 2 | 2008 | 151 | 0.030 |
Why?
|
| Periodontal Diseases | 1 | 1995 | 17 | 0.030 |
Why?
|
| Postoperative Period | 2 | 1993 | 130 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1160 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2014 | 9 | 0.030 |
Why?
|
| Citrate (si)-Synthase | 1 | 2014 | 5 | 0.030 |
Why?
|
| Calcium | 2 | 1988 | 583 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2014 | 110 | 0.030 |
Why?
|
| Tryptamines | 1 | 2014 | 13 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 73 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 798 | 0.030 |
Why?
|
| Glucagon | 1 | 2014 | 36 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2013 | 29 | 0.030 |
Why?
|
| Blood Pressure | 4 | 1991 | 524 | 0.030 |
Why?
|
| Animals | 7 | 2014 | 21341 | 0.030 |
Why?
|
| Gold | 1 | 1996 | 235 | 0.030 |
Why?
|
| Lysine | 1 | 2014 | 94 | 0.030 |
Why?
|
| Triazoles | 1 | 2014 | 63 | 0.020 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 86 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 1996 | 227 | 0.020 |
Why?
|
| Sampling Studies | 2 | 2005 | 65 | 0.020 |
Why?
|
| Food | 1 | 2014 | 76 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2014 | 144 | 0.020 |
Why?
|
| Age Factors | 4 | 2005 | 1579 | 0.020 |
Why?
|
| Arginine | 1 | 2014 | 136 | 0.020 |
Why?
|
| Family | 1 | 2015 | 245 | 0.020 |
Why?
|
| Child | 5 | 1989 | 4601 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 453 | 0.020 |
Why?
|
| Program Evaluation | 1 | 1994 | 488 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 218 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2014 | 222 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 295 | 0.020 |
Why?
|
| Hemodynamics | 3 | 1991 | 251 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1996 | 346 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 286 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2012 | 59 | 0.020 |
Why?
|
| Histamine Release | 1 | 1991 | 3 | 0.020 |
Why?
|
| Leukotrienes | 1 | 1991 | 4 | 0.020 |
Why?
|
| Prostaglandins | 1 | 1991 | 18 | 0.020 |
Why?
|
| Lymph | 1 | 1991 | 10 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1991 | 19 | 0.020 |
Why?
|
| Cardioplegic Solutions | 1 | 1991 | 9 | 0.020 |
Why?
|
| Heart Arrest, Induced | 1 | 1991 | 13 | 0.020 |
Why?
|
| Anaphylaxis | 1 | 1991 | 41 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 1991 | 3 | 0.020 |
Why?
|
| Technology Assessment, Biomedical | 1 | 1991 | 12 | 0.020 |
Why?
|
| Mass Screening | 1 | 1997 | 695 | 0.020 |
Why?
|
| Incidence | 3 | 2003 | 1412 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2014 | 395 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1594 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1985 | 0.020 |
Why?
|
| Vaccination | 2 | 2005 | 374 | 0.020 |
Why?
|
| Mitochondria | 1 | 2014 | 402 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 907 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 871 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 1989 | 12 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 1991 | 299 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 868 | 0.020 |
Why?
|
| Gastric Acid | 1 | 1989 | 9 | 0.020 |
Why?
|
| Tubocurarine | 1 | 1988 | 2 | 0.020 |
Why?
|
| Myocardium | 1 | 1991 | 301 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 2154 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 1988 | 30 | 0.020 |
Why?
|
| Nursing Homes | 1 | 1994 | 679 | 0.020 |
Why?
|
| Creatinine | 1 | 1989 | 135 | 0.020 |
Why?
|
| Lung | 2 | 1991 | 967 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 1989 | 96 | 0.020 |
Why?
|
| Rural Health | 1 | 2008 | 16 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2008 | 57 | 0.020 |
Why?
|
| Glucose | 1 | 1991 | 476 | 0.020 |
Why?
|
| Drug Costs | 1 | 2008 | 55 | 0.020 |
Why?
|
| Plasma | 1 | 1988 | 38 | 0.020 |
Why?
|
| Craniotomy | 1 | 2007 | 20 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2008 | 49 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1988 | 213 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 250 | 0.020 |
Why?
|
| Feedback | 1 | 1987 | 91 | 0.020 |
Why?
|
| Mice | 2 | 2014 | 11114 | 0.020 |
Why?
|
| Health Services | 1 | 2008 | 80 | 0.020 |
Why?
|
| Phenylephrine | 1 | 1987 | 18 | 0.020 |
Why?
|
| Propanolamines | 1 | 1987 | 10 | 0.020 |
Why?
|
| Propranolol | 1 | 1987 | 22 | 0.020 |
Why?
|
| Metoprolol | 1 | 1987 | 17 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1989 | 466 | 0.020 |
Why?
|
| Anesthesiology | 1 | 1987 | 42 | 0.020 |
Why?
|
| Insulin | 1 | 1991 | 696 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Cholesterol | 1 | 2008 | 261 | 0.020 |
Why?
|
| Body Weight | 1 | 1988 | 375 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2008 | 171 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1988 | 162 | 0.020 |
Why?
|
| Atracurium | 1 | 1986 | 2 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1986 | 19 | 0.020 |
Why?
|
| Histamine | 1 | 1986 | 21 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 62 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1988 | 740 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3472 | 0.020 |
Why?
|
| Neoplasms | 1 | 1997 | 1362 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 364 | 0.010 |
Why?
|
| Mycobacterium avium | 1 | 1985 | 5 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 292 | 0.010 |
Why?
|
| BCG Vaccine | 2 | 1996 | 56 | 0.010 |
Why?
|
| Mycobacterium Infections | 1 | 1985 | 15 | 0.010 |
Why?
|
| Thymectomy | 1 | 1985 | 35 | 0.010 |
Why?
|
| Heart Rate | 1 | 1987 | 331 | 0.010 |
Why?
|
| Myasthenia Gravis | 1 | 1985 | 10 | 0.010 |
Why?
|
| Child Day Care Centers | 1 | 2005 | 9 | 0.010 |
Why?
|
| Maternal Age | 1 | 2005 | 33 | 0.010 |
Why?
|
| Marital Status | 1 | 2005 | 44 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1986 | 203 | 0.010 |
Why?
|
| Mycobacterium | 1 | 1985 | 37 | 0.010 |
Why?
|
| Plasma Exchange | 1 | 1985 | 24 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2007 | 274 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 735 | 0.010 |
Why?
|
| Psychometrics | 1 | 2007 | 392 | 0.010 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2007 | 223 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1986 | 195 | 0.010 |
Why?
|
| Forecasting | 1 | 2005 | 230 | 0.010 |
Why?
|
| Kansas | 1 | 2003 | 3 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 741 | 0.010 |
Why?
|
| Family Characteristics | 1 | 2003 | 46 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1557 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 554 | 0.010 |
Why?
|
| Aging | 1 | 1989 | 762 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 610 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 414 | 0.010 |
Why?
|
| Breast Feeding | 1 | 2005 | 164 | 0.010 |
Why?
|
| Urban Population | 1 | 2003 | 200 | 0.010 |
Why?
|
| Tuberculosis | 2 | 1996 | 305 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 990 | 0.010 |
Why?
|
| United States Environmental Protection Agency | 1 | 2001 | 7 | 0.010 |
Why?
|
| Vascular Resistance | 2 | 1991 | 47 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1988 | 2284 | 0.010 |
Why?
|
| Parents | 1 | 2005 | 410 | 0.010 |
Why?
|
| Pulmonary Circulation | 2 | 1991 | 27 | 0.010 |
Why?
|
| Mortality | 1 | 2001 | 160 | 0.010 |
Why?
|
| Prevalence | 1 | 2003 | 1438 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 2483 | 0.010 |
Why?
|
| Health Care Rationing | 1 | 1997 | 21 | 0.010 |
Why?
|
| Binomial Distribution | 1 | 1996 | 4 | 0.010 |
Why?
|
| Health Expenditures | 1 | 1997 | 121 | 0.010 |
Why?
|
| Dental Scaling | 1 | 1995 | 1 | 0.010 |
Why?
|
| Root Planing | 1 | 1995 | 2 | 0.010 |
Why?
|
| Periodontal Index | 1 | 1995 | 4 | 0.010 |
Why?
|
| Periodontal Attachment Loss | 1 | 1995 | 2 | 0.010 |
Why?
|
| Muscle Rigidity | 1 | 1994 | 7 | 0.010 |
Why?
|
| Pressure Ulcer | 1 | 1994 | 34 | 0.010 |
Why?
|
| New York | 1 | 1994 | 144 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2006 | 6823 | 0.010 |
Why?
|
| Restraint, Physical | 1 | 1994 | 57 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 1995 | 116 | 0.010 |
Why?
|
| Meclofenamic Acid | 1 | 1991 | 1 | 0.010 |
Why?
|
| Thromboxane-A Synthase | 1 | 1991 | 1 | 0.010 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1991 | 1 | 0.010 |
Why?
|
| Dinitrophenols | 1 | 1991 | 5 | 0.010 |
Why?
|
| SRS-A | 1 | 1991 | 2 | 0.010 |
Why?
|
| Leukotriene E4 | 1 | 1991 | 2 | 0.010 |
Why?
|
| Chromones | 1 | 1991 | 18 | 0.010 |
Why?
|
| Inpatients | 1 | 1994 | 313 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1991 | 35 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1991 | 29 | 0.010 |
Why?
|
| Phosphocreatine | 1 | 1991 | 25 | 0.010 |
Why?
|
| Comorbidity | 1 | 1994 | 1112 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 149 | 0.010 |
Why?
|
| Lactates | 1 | 1991 | 28 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 1991 | 43 | 0.010 |
Why?
|
| Glycogen | 1 | 1991 | 40 | 0.010 |
Why?
|
| Imidazoles | 1 | 1991 | 82 | 0.010 |
Why?
|
| Sheep | 1 | 1991 | 189 | 0.010 |
Why?
|
| Adenosine Monophosphate | 1 | 1991 | 30 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1991 | 342 | 0.000 |
Why?
|
| Nifedipine | 1 | 1989 | 18 | 0.000 |
Why?
|
| Vasoconstriction | 1 | 1989 | 22 | 0.000 |
Why?
|
| Research | 1 | 1990 | 194 | 0.000 |
Why?
|
| Vasodilation | 1 | 1989 | 36 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1989 | 493 | 0.000 |
Why?
|
| Citrates | 1 | 1988 | 19 | 0.000 |
Why?
|
| Hypoxia | 1 | 1989 | 119 | 0.000 |
Why?
|
| Recovery Room | 1 | 1987 | 3 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1988 | 175 | 0.000 |
Why?
|
| Risk Management | 1 | 1987 | 36 | 0.000 |
Why?
|
| Rats | 1 | 1991 | 1995 | 0.000 |
Why?
|
| Documentation | 1 | 1987 | 132 | 0.000 |
Why?
|
| Agglutination | 1 | 1985 | 5 | 0.000 |
Why?
|
| Water Supply | 1 | 1985 | 16 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1985 | 231 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1985 | 200 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1988 | 1412 | 0.000 |
Why?
|
| Respiration, Artificial | 1 | 1985 | 294 | 0.000 |
Why?
|
| Intensive Care Units | 1 | 1985 | 420 | 0.000 |
Why?
|
| Length of Stay | 1 | 1985 | 824 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 1985 | 2694 | 0.000 |
Why?
|